Iron chelators have been shown to reduce mitochondrial function, alter nucleotide synthesis, and inhibit tumor growth, underlining iron’s pivotal role in CRC cell metabolism.[26] Research has documented significant alterations in iron metabolism-related molecules such as ferritin, transferrin, and serum iron in CRC patients, potentially influencing tumor occurrence and progression.[17]. The gene discussed is TF; the disease is colorectal carcinoma.